Idenix Pharmaceuticals, Inc.Cambridge, MA United States
Company Description
Idenix Pharmaceuticals is not suffering from an identity crisis -- it is clear in its focus on identifying treatments for viral diseases. The firm develops orally administered drugs to combat chronic hepatitis C (HCV). It has one marketed drug for hepatitis B (HBV), Telbivudine, sold under the brand names Tyzeka in the US and Sebivo internationally. It markets the product with
| 60 Hampshire St. | Phone: 617-995-9800 | http://www.idenix.com |
| Cambridge, MA 02139 | Fax: 617-995-9801 | 
Map This Company |
| United States |
Try a Full Premium Subscription
Access over 85 million companies
Call (866) 443-3939 or
Prepare for your Sales call
Try a Small Business Subscription
Starting $89 per month
Idenix Pharmaceuticals, Inc. Rankings
| Russell 2000 (June 2011) |
Executives
| 27 executives listed for Idenix Pharmaceuticals, Inc.'s Cambridge, MA location. | ||
| President, CEO, and Director | Ronald Renaud | |
|---|---|---|
| EVP and Chief Scientific Officer | David Standring | |
| EVP Clinical Development and Chief Medical Officer | Douglas Mayers | |
Financials
| Company Type | Public - NASDAQ: IDIX Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 105 |
DNBiLeverage D&B's credit assessment tools to positively impact
your business. Get the scoop on Idenix Pharmaceuticals, Inc. now.
- Reduce risk.
- Drive greater profitability.
- Increase cash flow.
